Kira Gritsman
@Gritsman_lab
Physician-scientist investigating signaling and self-renewal in leukemia and hematopoietic stem cells. Posts are my own.
I am so happy to meet friends at ASH and enjoy the amazing talks! This is a special year. Join us at the ASH Plenary Session. My very talented postdoc, Sen Zhang, will present her work on the role of PF4 in Hematopoietic Stem Cell Aging 👏👏👏 #ASH2024 @ASH_hematology @uiccom
We are excited to announce that The Myeloid Workshop is back on under ASH this year and will be held on Friday, Dec 5, from 3-7PM. ...👇
In our study just published in @BloodCancerJnl Outdoor Air Pollution(OAP) , particularly PM2.5 was associated with a trend towards worse survival in #multiplemyeloma patients treated in a historically redlined area - Bronx, NY. @Einstein_SCI @MontefioreNYC @EinsteinMed
Fine particulate matter exposure is linked to worse myeloma outcomes in a diverse urban cohort | Blood Cancer Journal @aditishasMD nature.com/articles/s4140…
We are very excited to officially launch our single cell proteomics service!! Please, check out our website if you want to work with us! sidolilab.org/single-cell
Check out our new preprint on an epigenetic resistance mechanism to PI3 kinase inhibition in AML and a new combination therapy with an EZH1/2 inhibitor that depletes leukemic stem cells! Great effort by @TheHematoPoet and the whole team
So excited to share a pre-print of my thesis work! Check it out to see how we can leverage an epigenetic resistance mechanism to PI3K inhibitors to target leukemic stem cells!! (Spoiler alert: PRC2 is involved!) Really proud of this work conducted with @Gritsman_lab
Our trainees had a truly enriching experience at #KUHRTN2025 at @EmoryMedicine, Atlanta! They gained insights into career development, received valuable advice, and enjoyed connecting with field leaders and peers (@KUHR_Trainees) from across the country. bit.ly/3H529IZ
Congratulations to @SteidlUli on this very well deserved honor!
Congratulations to Ulrich G. Steidl, M.D., Ph.D., who is our 14th Annual Marshall S. Horowitz Faculty Lecturer. @EinsteinMed @MontefiorePeds @RFK_Center @i_jsmiles @EinsteinPHPM
So excited that our collaboration with @DShechter on a targetable PTM - glutamylation - on NPM1c in AML, led by @AlexSchurer and @HumairaIlyas8 is now on BiorXiv!
We discovered a new AML vulnerability: TTLL4 glutamylates NPM1c and helps leukemia cells thrive. Knock it down and cells differentiate and survival improves. Collab between our lab and @Gritsman_lab—funded by NIH and DoD/CDMRP. Preprint: bit.ly/42oZl09 /1
About a month after Donald Trump took office as the 47th US president, almost all grant-review meetings remain suspended at the US National Institutes of Health (NIH), preventing the world’s largest public funder of biomedical research from spending much of its US$47 billion…
🔥 Excited for our Phase 1 study Ven + 7+3 for Newly Diagnosed AML demonstrating 85% CR (86% MRD-neg) @BloodJournal @ MontefioreNYC @EinsteinMed @MontefioreNYC Eric J. Feldman @MendelGoldfing2 @mkonople @Amitvermamds @aditishasMD @Gritsman_lab #leusm doi.org/10.1182/blood.…
Really looking forward to this meeting!
I feel like we could all use something fun to look forward to right about now 👇 Abstract submission and registration are open for the FASEB Hematologic Malignancies meeting. This is always the BEST meeting!!! Please RT! events.faseb.org/event/hematolo…
🚨Apparently all NIH Study Sections have been suspended indefinitely. For those who don’t know, this means there won’t be any review of grants submitted to NIH Depending on how long this goes on for, this could lead to an interruption in billions in research funding.
Excited to share our latest contribution describing the role of inflammation in regulating defective hematopoiesis in RUNX1-familial platelet disorder & identifying CD74/mTORC/JAK axis as one of the drivers of inflammation @ScienceTM @OHSUKnight @OHSUNews science.org/doi/10.1126/sc…
Check out the talk by my amazing grad student, @GhezziIan this morning at #ASH2024. Using a novel mouse model, he’s been able to identify a rare population of dormant JAK2-mutant HSCs that drive disease propagation and therapy resistance in MPNs.
What plenary? Best of #ASH2024 @DrSDNimer Respect 🙌 #miaminights @SylvesterCancer
Check out our new review by the amazing Alexandra Schurer and Shira Glushakow-Smith @TheHematoPoet on chromatin modifiers in AML!@EinsteinCellBio @Einstein_SCI @einstein_mstp @EinsteinPhD
Overwhelmed by all of the exciting advancements surrounding chromatin modifiers in AML? Do you find it hard to keep track of all the new menin inhibitors? Well good news, we’ve just published the perfect review for you in @StemCellsTM academic.oup.com/stcltm/advance… @Gritsman_lab
Congratulations Teresa! Well deserved!
Congratulations to Dr. Teresa V. Bowman (@Bowmaniacs_Lab ) from @Einstein_SCI on being the inaugural recipient of the Dr. Fernando Macian-Juan Award for Excellence in Graduate Student Mentoring! The ceremony will be held on December 12, 2024. More details: bit.ly/3CUzPqs
Thrilled to learn from Dr. Anna E. Beaudin @BeaudinLab @UofUHematology about the lasting impact of early-stage blood cells and prenatal nutrients on hematopoiesis and human disease. Great discussions with @Einstein_SCI faculty over dinner! @EinsteinMed
Thrilled to welcome Dr. Anna E. Beaudin (@BeaudinLab) from @UofUHematology for our Stem Cell Institute seminar on the role of extrinsic inputs in developmental hematopoiesis, Monday, November 18th at 3 PM! (Hosted by @Bowmaniacs_Lab & @The_Ito_Lab) @EinsteinCellBio @EinsteinMed
We had fun closing out the season on our lab apple picking trip today!
🎉Excited to present our latest work out today @Nature 1.What gives a leukemia its phenotype – the oncogenic driver or the differentiation stage of the cell-of-origin? 2.Why do RAS mutations always happen late in AML? 3.Who will relapse after VEN? nature.com/articles/s4158…